Novanta Inc (NOVT) Stock Price & Analysis
Novanta Inc (NOVT) fell 1.20% to USD 141.54 as of July 25, 2026 at 20:14 UTC, according to Nexqual real-time market data.
NOVT last closed at USD 143.26; the session ranged USD 139.43–144.4 on volume of 349,596 shares. Market capitalization is $5.04B, with a 52-week range of USD 98.27–171.85 (NMS). Source: Nexqual, July 25, 2026 at 20:14 UTC.
Key Statistics (as of July 25, 2026 at 20:14 UTC)
| Price | USD 141.54 |
|---|---|
| Change | ▼ 1.20% (down) |
| Previous Close | USD 143.26 |
| Open | USD 143.01 |
| Day Range | USD 139.43 – 144.4 |
| 52-Week Range | USD 98.27 – 171.85 |
| Volume | 349,596 shares |
| Market Cap | $5.04B |
| Exchange | NMS |
Technical Analysis (NOVT)
Nexqual's technical model rates NOVT "SELL" based on 1 bullish and 5 bearish signals across 125 daily candles, as of July 25, 2026 at 20:14 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 39.08 (neutral) |
| vs SMA50 | Below (USD 155.38) |
| MACD | -3.24 (negative) |
Analyst Ratings (NOVT)
Wall Street analysts rate NOVT "None" based on 2 analysts, with a mean price target of USD 175 (range USD 170–180), per Nexqual as of July 25, 2026 at 20:14 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 2 |
| Mean Target | USD 175 |
| High Target | USD 180 |
| Low Target | USD 170 |
| Buy / Hold / Sell | 3 / 0 / 0 |
Earnings (NOVT)
| Next Earnings Date | 2026-08-05 |
|---|---|
| EPS Estimate | USD 0.83 |
| Revenue Estimate | $262.30M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 0.81 vs est 0.78 ▲ beat |
| 2025-12-31 | USD 0.91 vs est 0.88 ▲ beat |
| 2025-09-30 | USD 0.87 vs est 0.82 ▲ beat |
| 2025-06-30 | USD 0.76 vs est 0.73 ▲ beat |
Source: Nexqual, July 25, 2026 at 20:14 UTC.
Financials & Fundamentals (NOVT)
| Total Revenue | $1.00B |
|---|---|
| Revenue Growth (YoY) | +10.40% |
| Gross Margin | +44.23% |
| Operating Margin | +11.70% |
| Profit Margin | +5.35% |
| ROE | +5.16% |
| Debt / Equity | 22.22 |
| Current Ratio | 3.56 |
| Total Cash | $388.80M |
| Total Debt | $291.34M |
| Free Cash Flow | $87.25M |
Source: Nexqual, July 25, 2026 at 20:14 UTC.
Financial Health Score (NOVT)
Nexqual rates Novanta Inc's overall financial health "Solid" across five dimensions, as of July 25, 2026 at 20:14 UTC.
| Growth | Mixed — Revenue +3.3% YoY (annual), slow |
|---|---|
| Profitability | Strong — Gross margin 44%, operating 12% |
| Balance Sheet | Strong — $389M cash vs $291M debt, net cash position |
| Cash Flow | Solid — FCF $87M, 9% margin |
| Efficiency | Mixed — ROE 5%, ROA 4.6% |
Ownership (NOVT)
| Insider Ownership | +0.75% |
|---|---|
| Institutional Ownership | +119.63% |
| Shares Outstanding | 35.61M |
| Float | 35.35M |
| Short % of Float | +17.23% |
Source: Nexqual, July 25, 2026 at 20:14 UTC.
Leadership (NOVT)
Novanta Inc is led by Matthijs Glastra (age 56), CEO & Chairman of the Board, per Nexqual as of July 25, 2026 at 20:14 UTC.
| CEO & Chairman of the Board | Matthijs Glastra (age 56) |
|---|---|
| Chief Financial Officer | Robert J. Buckley (age 51) |
| Co-Chief Operating Officer of Automation Enabling Technologies | Charles G. Ravetto (age 54) |
| Co-Chief Operating Officer of Medical Solutions | John Lesica (age 49) |
| Senior Vice President of Corporate Development | Nissia Sabri |
Major Backers & Investors (NOVT)
Notable institutional backers of Novanta Inc include Price (T.Rowe) Associates Inc, Allspring Global Investments Holdings, LLC, Conestoga Capital Advisors, LLC, according to Nexqual as of July 25, 2026 at 20:14 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Price (T.Rowe) Associates Inc | 4.73% |
| Allspring Global Investments Holdings, LLC | 4.71% |
| Conestoga Capital Advisors, LLC | 3.84% |
| Congress Asset Management Co | 2.58% |
| Geneva Capital Management LLC | 2.47% |
| Conestoga Funds-Conestoga Small Cap Fund | 1.88% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 18.44% |
| BlackRock | 17.83% |
| State Street | 3.55% |
| Geode Capital | 2.48% |
Source: Nexqual, July 25, 2026 at 20:14 UTC.
From Novanta Inc's Latest SEC 10-K Filing (filed 2026-02-23)
Key Strengths & Strategy (as disclosed to the SEC)
- Novanta Inc., together with its subsidiaries, provides precision medicine, precision manufacturing, medical solutions, robotics and automation solutions, and advanced surgery solutions in the United States and internationally.
- The company operates Automation Enabling Technologies and Medical Solutions segments.
- The Precision Medicine and Manufacturing segment designs, manufactures, and markets laser beam steering and scanning solutions, laser sources, robotic and precision motion, robotic end-of-arm tooling, and bearing spindles.
- This segment serves advanced industrial processes, advanced industrial and medical robotics, other medical and life science automation applications, and medical laser procedures, such as ophthalmology applications.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| SPSC | SPS Commerce, Inc. | USD 61.16 | ▲ 1.73% |
| LFUS | Littelfuse, Inc. | USD 404.86 | ▼ 2.7% |
| VPG | Vishay Precision Group, Inc. | USD 104.44 | ▼ 5.25% |
| NSIT | Insight Enterprises, Inc. | USD 117.65 | ▼ 0.19% |
| CNXN | PC Connection, Inc. | USD 81.23 | ▲ 0.51% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 20:14 UTC. This page is informational and not investment advice.